The clinical results for SequestOx, now that we disclosed what the product is, will be presented at various pain conferences this year. So far we have two -- possibly three lines up for these presentations act. We have now announced that SequestOx, ELI-200 are oxycodone, the current market for the generic part is $400 million.
I can launch SequestOx with what we have but we have our eye on the future just like you do when you are talking about. We are a small company, however a small percentage of what Pfizer could bring in will send our stocks through the roof. We share the same technology as Pfizer have for their pharmacological approach. We have our patents on our polymer, they have theirs on there. They have made their product into multi million dollar or billion dollar product and we need to do the same thing. It may not affect Pfizer a lot if they make a 100 million or 200 million but to us the stock will go through the roof. I am not promising anybody that that’s what’s going to happen but I need to be careful on what I say on these calls. But you are right, a small little percentage of that profit, you make $100 million and even if you had a billion shares outstanding, on a PE ratio of 20 the stock will go to several dollars.
News 
Market Data 
Discover 
